Get the Stockscreener App
3.20
3.51%
-0.1165
After Hours:
3.20
Intensity Therapeutics Inc stock is traded at $3.20, with a volume of 18,592.
It is down -3.51% in the last 24 hours and down -14.66% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
See More
Previous Close:
$3.3165
Open:
$3.1868
24h Volume:
18,592
Relative Volume:
1.45
Market Cap:
$44.90M
Revenue:
-
Net Income/Loss:
$-10.54M
P/E Ratio:
-1.4153
EPS:
-2.261
Net Cash Flow:
$-7.21M
1W Performance:
+0.79%
1M Performance:
-14.66%
6M Performance:
-17.10%
1Y Performance:
+4.92%
1-Day Range:
$3.1648
$3.40
1-Week Range:
$2.9464
$3.40
52-Week Range:
$2.0101
$11.44
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
61 WILTON ROAD, 3RD FLOOR, WESTPORT
Intensity Therapeutics Inc Stock (INTS) Latest News
INTSIntensity Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22) - PR Newswire
Balancing Decisions Around Breast Cancer Treatment and Fertility, Breastfeeding - Curetoday.com
Intensity Therapeutics grants stock options to top executives By Investing.com - Investing.com South Africa
Intensity Therapeutics grants stock options to top executives - Investing.com
Biliary Tumor Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - Barchart
SONIRE’s HIFU Therapy System Designated as Breakthrough Device by FDA - BioSpace
SONIRE's HIFU Therapy System Designated as Breakthrough Device by FDA - The Manila Times
Cholangiocarcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Thoracic Re-irradiation With Definitive External Beam Radiation Therapy Using Intensity Modulated Radiation Therapy: A Case Report - Cureus
There is Nothing Pink About Breast Cancer - Curetoday.com
Head and Neck Cancer Therapeutics Market Overview: Breakthrough Treatments, Technological Innovations, and ... - WhaTech
An Analysis of Ideaya Biosciences Inc (IDYA)’s Potential Price Growth - Knox Daily
Weekly Investment Analysts’ Ratings Changes for Incyte (INCY) - Defense World
Inogen: Upside Seems Limited After Big Move Up (NASDAQ:INGN) - Seeking Alpha
InvenTrust Properties (NYSE:IVT) Sees Strong Trading Volume - Defense World
Skandinaviska Enskilda Banken AB publ Increases Position in Itron, Inc. (NASDAQ:ITRI) - Defense World
Ideaya Biosciences price target lowered to $52 from $54 at Wedbush - TipRanks
Hoosier Hysterics Podcast: Sisley commits, plus IUWBBs Shay Ciezki and Karoline Striplin - 247Sports
Ideaya Biosciences should be bought on weakness, says Citi - TipRanks
Intapp, Inc. (NASDAQ:INTA) Shares Sold by Hood River Capital Management LLC - MarketBeat
(TIL) Long Term Investment Analysis - Stock Traders Daily
Itim Group PLC Announces Strong Mid-Year Financials - TipRanks
ITT Educational Services (OTCMKTS:ESINQ) Stock Price Passes Above Two Hundred Day Moving Average of $0.00 - Defense World
InvenTrust Properties Corp. Announces Upsizing and Pricing of Common Stock Offering - StockTitan
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Intense Technologies Limited's (NSE:INTENTECH) CEO For Now - Simply Wall St
US FDA Closes Out Problem Applications One Federal Register Notice At A Time - Pink Sheet
Ideaya Biosciences price target lowered to $66 from $68 at Stifel - TipRanks
BTIG maintains $62 target on Ideaya Biosciences stock - Investing.com
From Statins to PSCK9 Inhibitors: Choosing the Right Therapy for Cholesterol - Pharmacy Times
Intercontinental Exchange, Inc. (NYSE:ICE) Shares Sold by Interval Partners LP - Defense World
ILLIT Comeback 'I'll Like You' Mini-Album: Release Date, Tracklist - J-14
Integra Lifesciences Holdings Corp (IART) Becoming More Attractive for Investors - Knox Daily
Itau Unibanco Holding S.A. Acquires New Position in Incyte Co. (NASDAQ:INCY) - Defense World
ILLIT Announce First Comeback With Upcoming Mini-Album ‘I’LL LIKE YOU’ - Billboard Philippines
ILLIT announces 2nd mini-album I'LL LIKE YOU, set for October 21 release, marking comeback 7 months after debut - PINKVILLA
ILLIT flaunts 'candid charm' in upcoming EP 'I'll Like You' - ABS-CBN News
ILLIT to Make a Comeback After 7 Months with New Album in October - KBIZoom
Itau Unibanco Holding S.A. Purchases New Shares in Intuitive Surgical, Inc. (NASDAQ:ISRG) - Defense World
ILLIT announces the date for their first comeback - Music Mundial News
Update: ILLIT Shares New Brand Film For Upcoming “I’LL LIKE YOU” Comeback - soompi
Pacer Advisors Inc. Acquires 1,175,857 Shares of Titan International, Inc. (NYSE:TWI) - Defense World
ITM Power (OTCMKTS:ITMPF) Stock Price Down 4.1% - Defense World
Titan Machinery Inc. (NASDAQ:TITN) Given Average Rating of "Hold" by Brokerages - MarketBeat
ITM Power (OTCMKTS:ITMPF) Trading Down 4.1% - MarketBeat
Thrivent Financial for Lutherans Sells 30,265 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) - Defense World
Thrivent Financial for Lutherans Buys 109,795 Shares of Intercontinental Exchange, Inc. (NYSE:ICE) - Defense World
Pacer Advisors Inc. Buys 2,676,851 Shares of Incyte Co. (NASDAQ:INCY) - Defense World
First Eagle Investment Management LLC Raises Stake in Iteris, Inc. (NASDAQ:ITI) - Defense World
Intensity Therapeutics shares rise on Buy rating from Brookline Capital - Investing.com
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.11%
0.50%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):